Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
MEI Pharma, Inc is a biotechnology business based in the US. MEI Pharma shares (MEIP) are listed on the NASDAQ and all prices are listed in US Dollars. MEI Pharma employs 51 staff and has a trailing 12-month revenue of around USD$31.6 million.
|Latest market close||USD$2.91|
|52-week range||USD$0.72 - USD$4.46|
|50-day moving average||USD$2.8283|
|200-day moving average||USD$3.141|
|Wall St. target price||USD$9.45|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.754|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||0.34%|
|1 month (2020-11-05)||4.30%|
|3 months (2020-09-04)||18.29%|
|6 months (2020-06-05)||-21.98%|
|1 year (2019-12-05)||50.00%|
|2 years (2018-12-04)||3.93%|
|3 years (2017-12-05)||29.33%|
|5 years (2015-12-04)||88.96%|
Valuing MEI Pharma stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MEI Pharma's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
MEI Pharma's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 20.6. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MEI Pharma's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||USD$31.6 million|
|Gross profit TTM||USD$26.2 million|
|Return on assets TTM||-12.15%|
|Return on equity TTM||-69.62%|
|Market capitalisation||USD$322.9 million|
TTM: trailing 12 months
There are currently 7.4 million MEI Pharma shares held short by investors – that's known as MEI Pharma's "short interest". This figure is 4% down from 7.7 million last month.
There are a few different ways that this level of interest in shorting MEI Pharma shares can be evaluated.
MEI Pharma's "short interest ratio" (SIR) is the quantity of MEI Pharma shares currently shorted divided by the average quantity of MEI Pharma shares traded daily (recently around 564580.66971081). MEI Pharma's SIR currently stands at 13.14. In other words for every 100,000 MEI Pharma shares traded daily on the market, roughly 13140 shares are currently held short.
However MEI Pharma's short interest can also be evaluated against the total number of MEI Pharma shares, or, against the total number of tradable MEI Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case MEI Pharma's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 MEI Pharma shares in existence, roughly 70 shares are currently held short) or 0.0663% of the tradable shares (for every 100,000 tradable MEI Pharma shares, roughly 66 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against MEI Pharma.
Find out more about how you can short MEI Pharma stock.
We're not expecting MEI Pharma to pay a dividend over the next 12 months.
MEI Pharma's shares were split on a 1:6 basis on 19 December 2012. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your MEI Pharma shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for MEI Pharma shares which in turn could have impacted MEI Pharma's share price.
Over the last 12 months, MEI Pharma's shares have ranged in value from as little as $0.72 up to $4.46. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MEI Pharma's is 1.7029. This would suggest that MEI Pharma's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase II clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. The company has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and license agreements with Presage Biosciences, Inc. and CyDex Pharmaceuticals, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is headquartered in San Diego, California.
Everything we know about the Loha Co. IPO, plus information on how to buy in.
Everything we know about the Stem Inc IPO, plus information on how to buy in.
Everything we know about the View Inc IPO, plus information on how to buy in.
Everything we know about the Chime IPO, plus information on how to buy in.
Steps to owning and managing WPRT, with 24-hour and historical pricing before you buy.
Steps to owning and managing WBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WLK, with 24-hour and historical pricing before you buy.
Steps to owning and managing WDC, with 24-hour and historical pricing before you buy.
Steps to owning and managing WAL, with 24-hour and historical pricing before you buy.
Steps to owning and managing VSAT, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.